The Drug Controller General of India (DCGI) has directed the withdrawal of AstraZeneca's anti-cancer drug, Olaparib tablets, for patients who have undergone three or more prior lines of chemotherapy.
Advertisement
The Drug Controller General of India (DCGI) has directed the withdrawal of AstraZeneca's anti-cancer drug, Olaparib tablets, for patients who have undergone three or more prior lines of chemotherapy.
AstraZeneca has initiated the global withdrawal of its COVID-19 vaccine, Vaxzevria, citing a surplus of more advanced vaccine options targeting emerging variants of the virus.
The World Health Organization (WHO) has described the vaccine (Corona Vaccine) as "safe and effective for all people aged 18 and older", whose efficacy has made legal action "very rare".
The disclosure came to light through documents presented in the British High Court, where AstraZeneca acknowledged the existence of side effects associated with its vaccine.